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results recently published. Both vaccine effectiveness considered waning-effect 
over time. Outcomes and costs were both discounted 3% annually. Univariate and 
probabilistic sensitivity analyses (SA) were performed in order to test model robust-
ness. Results: Over a lifetime horizon and for a 629,747 COPD total population, 
PCV13 would prevent 2,224 inpatient-NBP, 3,134 outpatient-NBP and 210 IPD extra 
cases in comparison with CVP. Additionally, 398 related deaths would be averted. 
ICER was € 1,518 per quality adjusted life-year (QALY) gained for PCV13 versus CVP. 
PCV13 was found to be cost-effective versus CVP from 5 years horizon of model-
ling (1,302 inpatient-NBP, 1,835 outpatient-NBP and 182 deaths would be prevented 
(ICER € 25,573/QALY). The most influential parameter was time horizon and also 
other univariate SA confirmed model robustness. PSA results revealed that PCV13 
vaccination strategy was a cost-effective option on 100% of 1,000 simulations per-
formed. ConClusions: At the commonly accepted willingness-to-pay threshold 
of € 30,000/QALY gained, PCV13 vaccination in COPD-patients aged ≥ 50-years was 
a cost-effective strategy compared to CVP from 5 years to lifetime horizon in Spain.
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objeCtives: The objective of this study was to assess the cost-utility of tiotropium 
administrated through the Respimat inhaler as an add-on controller therapy on 
top of usual care in patients with severe persistent asthma from both the public 
payer’s and common (patient and National Health Fund - NHF) perspectives in 
Poland. Methods: The target population was adult patients with asthma, who 
are currently treated with the maintenance combination of inhaled corticoster-
oids (≥ 800 µg budesonide/day or equivalent) and long-acting β 2-agonists (LABAs) 
and who experienced one or more severe asthma exacerbation in the previous 
year (GINA – Global Initiative for Asthma 4-5 step). Tiotropium added to optimal 
standard of care (SOC) was compared with SOC alone (high-dose inhaled corti-
costeroid (ICS) and LABA). The Markov model with life-time horizon was con-
structed on the basis of existing model, from which also transition probabilities 
were retrieved. It included three asthma controlled states (controlled, partly con-
trolled, uncontrolled), three exacerbation health states (non-severe exacerbation, 
severe exacerbation, exacerbation with hospitalization) and death. Drug costs 
(tiotropium, ICS, LABAs), monitoring costs, rescue medication cost and costs of 
exacerbations (requiring hospitalization and other) were considered. Discount 
rates of 5% for costs and 3.5% for benefits were used. Results: Tiotropium+SOC 
generated 13.616 quality adjusted life years in the life-time horizon, whereas SOC 
was associated with 13.367 QALY. The incremental cost-effectiveness ratio (ICER) of 
tiotropium+SOC vs SOC alone was estimated to be € 16,137/QALY from the public 
payer’s perspective. The ICER from common (patient+NHF) perspective amounted 
to be € 23,923/QALY. Both results were below the cost-effectiveness threshold 
accepted for Poland (€ 27,275/QALY). ConClusions: Treatment of uncontrolled 
severe asthma with tiotropium delivered via Respimat added to high-dose inhaled 
corticosteroid and LABA is a cost-effective strategy in comparison to optimal SOC 
from both perspectives considered. The assessed technology is a response for 
existing unmet medical need in Poland.
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objeCtives: The aim of this study is to evaluate the economic impact and the clini-
cal consequences associated to the use of tiotropium, as an add-on to usual care, in 
patients with severe persistent asthma. Methods: A previously published 1-week 
cycle Markov model was used to estimate the cost per QALY. The model includes a 
death state and six states defined according to asthma control and severity of even-
tual relapses: controlled, partly controlled, uncontrolled, non-severe exacerbation, 
severe exacerbation without hospitalisation and severe exacerbation with hospitali-
sation. Progression is simulated for lifetime, assuming a 5% discount rate. Clinical 
data and utility weights for states without exacerbations come from two similar 
phase 3 randomised and double blind clinical trials, in which 912 patients were 
followed for 48 weeks. For exacerbation states, utility weights come from published 
literature. Costs were assessed for both the payers’ and NHS perspectives, being 
resource consumption estimated via an expert panel with five experienced pneu-
mologists. Results: Tiotropium enables patients to live more time with controlled 
asthma and to suffer less exacerbations, thus allowing an incremental gain of 0.18 
QALY (12.02 vs 11.84). For the payers’ perspective, tiotropium costs 7,038€ but savings 
with follow-up and exacerbations conduct to an incremental cost of 459€ . Therefore 
the cost per QALY is 2,576€ . The NHS co-payment rate for tiotropium is 69% but, as 
it benefits from most of the savings with follow-up and exacerbations, incremental 
cost is negative (-1.820€ ), making tiotropium a dominant alternative. Deterministic 
and probabilistic sensitivity analysis show that results are robust. ConClusions: 
Tiotropium enhances the quality of life of patients with severe persistent asthma, 
as it allows a better control of the disease and a reduction of exacerbations. This 
cost-utility analysis shows that, in the Portuguese setting, its use is cost-effective 
under the payers’ perspective and dominant under the NHS perspective.
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threshold recommendations (€ 30,000/QALY) found in the literature, the addition 
of tiotropium to the CT resulted in a cost-effective therapeutic option for the treat-
ment of persistent severe asthma in Spain. Key words: cost-effectiveness, asthma, 
tiotropium
PRS48
a SyStEmatic REviEW of maRkov modElS Evaluating  
multi-comPonEnt diSEaSE managEmEnt PRogRamS
Kirsch F
Ludwig-Maximilians-University Munich, Munich, Germany
objeCtives: For patients with chronic conditions disease management programs 
(DMPs) have been implemented to improve the process and quality of care and to 
reduce expenditures. The aim here is to present a systematic overview of Markov 
models evaluating the cost-effectiveness of DMPs; the focus is on the modeling 
approach for the multiple interventions. Further, the quality of the models and 
how the differences in structure and data used affect cost-effectiveness was evalu-
ated. Methods: The databases Pubmed, Embase, Business Source Complete, and 
EconLit were systematically searched for Markov models evaluating DMPs in chronic 
heart diseases (CHD), diabetes, COPD, asthma, and breast cancer. The quality of the 
models was evaluated with the help of two different quality appraisals. Results: 
15 studies met the inclusion criteria (eight CHD, two asthma, five diabetes). Most 
models extrapolate costs and effects of multi intervention in DMPs; only four stud-
ies combine clinical trials for single interventions to a DMP. In CHD, the results 
range from cost savings to additional costs of US$53,373 per quality-adjusted life 
year (QALY), in asthma from cost savings to additional costs of US$3,635 per QALY, 
and in diabetes from cost savings to additional costs of US$85,087 per QALY. In the 
Philips-quality-appraisal the overall scores vary from 39% to 62%, and in the ISPOR-
quality-appraisal from 31% to 58%. ConClusions: As most models incorporate the 
effects of complete DMPs, the contribution on the effect of individual treatments is 
not clear. A more flexible structure which allows to simply add other interventions 
to the DMP would be valuable, to enable prioritization of interventions based on 
incremental cost-effectiveness ratios. According to the results, it is difficult to say 
in which indication area DMPs are most cost-effective. More recently published 
models perform slightly better in both quality appraisals. Results are most sensitive 
to changes in transition probabilities and time horizon.
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objeCtives: There is no option of smoking cessation treatment reimbursed by 
public healthcare payers in the Czech Republic, except for small contributions paid 
by preventive funds of some health insurance companies. Tobacco dependence is 
a chronic, relapsing and lethal disease. Smoking harms nearly all organs in the 
body, causes many comorbidities and generally deteriorates health. The aim of 
this study is to compare costs and effectiveness of different treatment methods of 
tobacco dependence used in the Czech Republic from the perspective of the public 
healthcare payer. Methods: Discrete Event Simulation (DES) model developed in 
ARENA® was used to compare varenicline, bupropion and nicotine replacement 
therapy (NRT) as pharmacotherapy for tobacco dependence. The evaluation group 
(100% intervention followed by treatment mix) was compared with treatment mix 
excluding evaluation product. The model simulates smokers one by one depending 
on the baseline characteristics. Treatment response, duration of abstinence, time 
to next quit attempt or relapse is assigned individually to subjects using regres-
sion equations. Every subject is assigned an individual risk of developing smoking-
related conditions based on smoking status (smoker or former smoker). Chronic 
obstructive pulmonary disease, myocardial infarction, stroke and lung cancer were 
considered as smoking-related conditions. Incidence of smoking-related conditions 
leads higher mortality, lower quality of life and also to higher costs. DES models the 
benefits of smoking cessation in terms of reducing the risk of smoking-related con-
ditions and thus higher gain of QALYs and lower costs. Results: The ICER of vareni-
cline, bupropion and NRT compared to the currently used treatment mix reached 
1,229.74 € , 1,586.06 € and 3,572.23 € per QALY gained respectively. ConClusions: 
Varenicline generates the most QALYs and results in the largest cost savings com-
pared to other interventions. Therefore, varenicline can be considered the most 
cost-effective smoking cessation treatment in the Czech Republic.
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objeCtives: Patients with chronic obstructive pulmonary disease (COPD) are at 
elevated risk of pneumococcal infection. A 13-valent-pneumococcal-conjugate 
vaccine (PCV13) was approved for adult protection against invasive disease and 
pneumonia caused by S. pneumoniae. This study estimated the incremental cost-
effectiveness ratio (ICER) of vaccinating COPD-patients ≥ 50-years with PCV13 
compared to current vaccination policy (CVP) with 23-valent-pneumococcal-poly-
sacharide vaccine. Methods: A Markov model accounting for risks and costs for 
all-cause non-bacteremic pneumonia (NBP) and invasive pneumococcal disease 
(IPD) was developed. All parameters such as disease incidence, utilities, and costs 
(€ 2015), were based on published data. The perspective of the analysis was that 
of the Spanish National Healthcare System, and the horizon of evaluation was 
lifetime in the base case. PCV13 effectiveness was based on CAPiTA clinical trial 
